Apr 30, 2010 | Laboratory Pathology
More multiplex and multi-analyte testing lies ahead for clinical pathology laboratories.
Several experts predict that clinical pathology laboratories will see the use of multiplex assays and multi-analyte diagnoses increase significantly in the near future. As this happens, both the science and the operations of clinical laboratories and pathology practices will grow in sophistication and complexity.
This week at the Executive War College on Laboratory and Pathology Management in New Orleans, Louisiana, almost 600 pathology and laboratory leaders gathered from 12 nations across the globe. During Wednesday’s general session, Thomas M. Grogan, M.D., Founder and Chief Scientific Advisor of Roche Ventana Medical Systems laid out his vision of how surgical pathology will evolve in the future.
(more…)
Apr 28, 2010 | Laboratory Pathology, News From Dark Daily
Speakers at the Executive War College discuss how their laboratories are supporting integration in support of better information flows and clinical service enhancements
As you read this, the second day of the 15th Annual Executive War College on Clinical and Pathology Laboratory Management is taking place in New Orleans, Louisiana. There is an enthusiastic crowd of pathologists, administrators, and lab managers in attendance.
During the opening session yesterday morning, a common theme among the speakers was the tighter integration of clinical pathology laboratory testing within the healthcare continuum. Probably the most innovative example was offered by Scott W. Binder, M.D., Senior Vice Chair of the Department of Pathology and Laboratory Medicine at the Geffen UCLA School of Medicine in Los Angeles California.
Executive War College 2010 is now underway in New Orleans.
(more…)
Apr 16, 2010 | Instruments & Equipment, Laboratory Pathology
Leica Microsystem acquires Genetix while Omnyx licenses patents from Olympus
More pathology laboratories are acquiring and deploying digital scanners and digital pathology systems. In response to the growing demand for digital pathology solutions, several prominent companies are extending their capabilities in virtual microscope slide technology. Over recent months, an acquisition and a licensing deal provide examples of the intense activity in the digital pathology marketplace.
The acquisition was done by Leica Microsystem, Inc., of Wetzlar, Germany. On March 10th, it announced its acquisition of Genetix, Ltd., based in New Milton, UK. The licensing deal involved Omnyx, LLC, of Pittsburgh, Pennsylvania, in an agreement that gives it access to certain patents held by Olympus Corporation. Both of these transactions occurred in March. Each was motivated by initiating the company’s need to further develop its technologies in support of whole slide imaging (WSI) and digital pathology systems.
(more…)
Apr 12, 2010 | Laboratory Pathology, Management & Operations, News From Dark Daily
Pathologists and clinical lab executives will hear perspectives from 80 speakers at the upcoming Executive War College on Lab and Pathology Management
For any pathologist or clinical laboratory executive interested in the future of the lab testing industry, there will be plenty of insights at the upcoming 15th Annual Executive War College on Laboratory and Pathology Management April 27-28 at the New Orleans Sheraton Hotel. Leading a line-up of 80 speakers are David King, CEO of Laboratory Corporation of America (NYSE: LH) and Thomas Grogan, M.D., Founder and Chief Scientific Advisor of Roche Ventana Medical Systems.
There’s lots of optimism about the future of laboratory testing. That’s because genetic and molecular testing is giving pathologists new tools to more precisely diagnose disease and determine appropriate therapies. LabCorp’s David King, will speak to how lab test data is the linchpin in the drive to more tightly integrate clinical care in ways to lift patient outcomes.
(more…)
Mar 22, 2010 | Laboratory News, Laboratory Pathology, News From Dark Daily
Some clinical labs use new pathology lab test technologies to deliver added value to physicians, patients, and payers
Clinical pathology laboratories in the United States and other developed countries across the globe face an unprecedented double-whammy. On one hand, the ongoing explosion of genetic and molecular knowledge gives pathologists and clinical laboratories incredible new tools for diagnosing disease and guiding therapy.
On the other hand, funding for government health programs in the United States and other developed countries is failing to keep pace with demand for health services and the need to pay for all the sophisticated molecular diagnostics and complex therapies now coming to market.
(more…)
